Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data

Nuclear Medicine Communications

Volumn 32, Issue 1, 2011, Pages 37-43

  Shanehsazzadeh, Saeed ^a   Lahooti, Afsaneh ^a   Sadeghi, Hamid Reza ^c   Jalilian, Amir Reza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

biodistribution; effective absorbed dose; gallium 67 cDTPA gonadorelin; gonadotropin releasing hormone

Indexed keywords

CYCLONE 30; GONADORELIN GA 67; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER WALL; BONE MARROW; BREAST; HUMAN; LIVER; LUNG; NONHUMAN; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RAT; WHOLE BODY RADIATION;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; GALLIUM RADIOISOTOPES; GONADOTROPIN-RELEASING HORMONE; HUMANS; PENTETIC ACID; RADIATION DOSAGE; RADIOMETRY; RATS;

EID: 78650309878     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328340b916     Document Type: Article

References (34)

1. Tang G, Wang M, Tang X, Luo L, Gan M. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F] fluoroethyl)-l-tyrosine as oncologic PET tracer. Appl Radiat Isot 2003; 58:219-225.
2. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18) F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
3. Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA, et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med 1998; 39:307-310.
4. 67GA-DTPA-ACTH based on distribution data in rats. Radiat Prot Dosimetry 2009; 134:79-86.
5. 67Ga]-DTPA-gonadorelin in normal rats. J Radioanal Nucl Chem 2008; 278:123-129.
6. Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971; 43:393-399.
7. Clayton RN. Gonadotropin releasing hormone: its action and receptors. J Endocrinol1989; 120:11-19.
8. Gründker C, Günthert AR, Hellriegel M, Emons G. Gonadotropin-releasing hormone (GnRH) agonistTriptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004; 151:619-628.
9. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev 2004; 25:235-275.
10. Marelli MM, Moretti RM, Januszkiewicz-Caulier J, Motta M, Limonta P. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 2006; 6:257-269.
11. Ratcliffe KE, Fraser HM, Sellar R, Rivier J, Millar RP Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. Endocrinology 2006; 147:571-579.
12. Jaeger LB, Banks WA, Varga JL, Schally AV. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci USA 2005; 102:12495-12500.
13. 67Ga. Appl Radiat Isot 2000; 52:551-556.
14. Snyder WS, Ford MR, Warner GG, Watson SB. 'S' absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet. New York, NY: Society of Nuclear Medicine; 1975:11.
15. Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet. New York, NY: Society of Nuclear Medicine; 1978:5 revised.
16. International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP publication 62. Stockholm, Sweden: ICRP; 1993.
17. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm 2005; 20:126-140.
18. 131I-19-Iodocholesterol: the pitfalls of using tissue concentration data-reply. J Nucl Med 1975; 16:248-249.
19. Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. In: Stelson A, Stabin M, Sparks R, editors. Sixth International radiopharmaceutical dosimetry symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1999. pp. 705-716.
20. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
21. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. New York, NY: Pergamon Press; 1993. ICRP Publication 23.
22. International Commissionon Radiological Protection. The 2007 Recommendations of the International Commission on Radiological Protection. International Commission on Radiological Protection, ICRP Publication103. Ann ICRP 2007; 37: 1-332.
23. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002; 43:92-96.
24. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al Pharmacokinetics and biodistribution of 111In-and 1 77Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 1 77Lu. J Nucl Med 2005; 46:634-641.
25. Lu J, Ichise M, Liow J, Ghose S, Vines D, Innis R. Biodistribution and radiation dosimetry of the serotonin transporter ligand 11 C-DASB determined from human whole-body PET. J Nucl Med 2004; 45:1555-1559. (Pubitemid 47618510)
26. Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S. In vitro and in vivo characterization of 11C-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002; 29:509-515.
27. 11C-DASB determined from whole-body imaging in non-human primates. Nucl Med Commun 2004; 25:81-86. (Pubitemid 38183955)
28. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Schmitt J, et al. Biodistribution and dosimetry of 1 77Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 2003; 18:593-599.
29. De Jong M, Breeman W, Bernhard B, Bakker W, Schaar M, Van Gameren A, et al. [177Lu-DOTA0, Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 1:628-633.
30. Lewis J, Wang M, Laforest R, Wang F, Erion J, Bugaj J, et al Toxicity and dosimetry of 1 77Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001; 94:873.
31. Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003; 44:1148-1155.
32. Deterding TA, Voraw JR, Wang CK, Eshima D, Eshima L, Keil R, et al. Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med 2001; 42:376-381.
33. Bélanger MJ, Krause SM, Ryan C, Sanabria-Bohorquez S, Li W, Hamill TG, et al. Biodistribution and radiation dosimetry of [18F] F-PEB in nonhuman primates. Nucl Med Commun 2008; 29:915-919.
34. Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [(18) F] 5-fluorouracil derived from pet-based and tissue-based methods in rats. Mol Imaging Biol 2008; 10:341-348.